ArticleInternational journal of molecular sciences2025
Regulation of Cell Cycle-Related Damage/Repair Mechanism and Oxidative Stress Status by Oroxylin A in Hepatocellular Carcinoma Cells.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma is a progressive tumor with an aggressive nature. Despite many treatment options, survival rates remain low. In this study, the effect of Orox A on hepatocellular carcinoma cells was investigated. Hep3B cells were treated with a range of Orox A, and cell viability was assessed by MTT assays. Subsequent analyses using RT-qPCR demonstrated alterations in the expression of DNA damage and repair genes. To determine the damage in cancer cells, the amount of 8-OHdG and NO in the cells was measured by the ELISA method. Additionally, total antioxidant/oxidant status was measured, and the OSI value was calculated. Flow cytometry analysis was conducted to ascertain the specific cell cycle phase. The IC50 dose of Orox A for hepatocellular carcinoma cells was calculated to be 1385 μM at 24 h. According to the gene expression analysis results, NEIL1, OGG1, ATM and ATR gene expressions increased significantly, while APEX1 gene expression decreased significantly. The amount of 8-OHdG dramatically increased in cancer cells treated with Orox A, whereas the level of NO significantly decreased. Total antioxidant status (TAS) and total oxidant status (TOS) were significantly decreased in Orox A-applied cancer cells, and the oxidative stress index (OSI) was significantly increased. Flow cytometry analysis revealed that Orox A treatment caused G2/M phase arrest in the cell cycle. These findings collectively suggest that Orox A exerts cytotoxic effects on Hep3B cells through mechanisms involving DNA damage, oxidative stress, and cell cycle modulation, making it a promising candidate for further anticancer therapy development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.